Key Development The Drug Administration of Vietnam (DAV), operating under the Ministry of Health, has formally issued two urgent nationwide... Read more
Category: Uncategorized
Expanding the Orphan Franchise: Sanofi’s Next-Gen Nexviazyme Secures Complete Phase III Efficacy to Supplant Myozyme in Infantile-Onset Pompe Disease
Key Development Global biopharmaceutical innovator Sanofi has officially released positive top-line data from its pivotal Phase III Baby-COMET clinical trial... Read more
Late-Stage Product Lifecycle Aggregation: Eli Lilly Divests Mainland China Commercial Rights for Blockbuster Verzenios to Innovent
Key Development Global biopharmaceutical leader Eli Lilly has formally executed a definitive strategic agreement transferring the mainland China commercialization rights... Read more
Geopolitical Biopharma Friction: U.S. House Committee Launches National Security Probe into Merck and AbbVie Clinical Trials in China
Key Development The chair of the U.S. House Select Committee on the Strategic Competition Between the United States and the... Read more
Geopolitical Biopharma Friction: U.S. House Committee Launches National Security Probe into Merck and AbbVie Clinical Trials in China
Key Development The chair of the U.S. House Select Committee on the Strategic Competition Between the United States and the... Read more
Rebounding in the DLBCL Matrix: AbbVie and Genmab Liquidate Monotherapy Setbacks with Landmark Epkinly Combo Victory
Key Development Biopharmaceutical aggregators AbbVie and Genmab have jointly released positive top-line data from their definitive Phase III Epcore DLBCL-4... Read more
Compliance Risk Governance: AstraZeneca Deploys $34 Million to Settle Texas ‘Free Nurses’ Medicaid Kickback Litigation
Key Development Global biopharmaceutical enterprise AstraZeneca has formally agreed to a $34 million financial settlement to resolve a high-profile civil... Read more
Enforcing Regional Safety Standards: Drug Administration of Vietnam Decrees Nationwide Recall of 4 Anti-Dandruff Shampoos Containing Banned Ingredient Clotrimazole
Key Development The Drug Administration of Vietnam (DAV), operating under the Ministry of Health, has formally issued an emergency regulatory... Read more
Post-M&A Executive Realignment: China’s Livzon Group Assumes Control of Imexpharm (IMP), Directing a 6% Cash Dividend
Key Development Imexpharm Pharmaceutical Joint Stock Company (Ticker: IMP)—a premier listed pharmaceutical manufacturer on the Vietnamese equity markets—has officially released... Read more









